celecoxib

celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also indicated for the management of acute pain and for the reduction of adenomatous polyps in patients with familial adenomatous polyposis. As a cyclooxygenase-2 (COX-2) selective inhibitor, it represents a distinct class within the broader NSAID family, developed to reduce gastrointestinal side effects associated with traditional non-selective NSAIDs.

Medical uses

Celecoxib is primarily prescribed for the symptomatic relief of osteoarthritis and rheumatoid arthritis, as endorsed by bodies like the American College of Rheumatology. It is also approved for the treatment of ankylosing spondylitis, juvenile rheumatoid arthritis, and the management of acute pain, such as that following dental procedures like wisdom tooth extraction. Furthermore, the U.S. Food and Drug Administration (FDA) has approved its use to reduce the number of adenomatous polyps in patients with familial adenomatous polyposis, following studies like the PreSAP Trial. Its use is generally guided by treatment recommendations from organizations such as the American Heart Association in patients with cardiovascular risk factors.

Adverse effects

Common adverse effects include dyspepsia, diarrhea, and abdominal pain, though its COX-2 selectivity reduces the risk of serious gastrointestinal bleeding compared to non-selective NSAIDs like ibuprofen. However, it carries an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, a concern highlighted by the withdrawal of the related drug rofecoxib (Vioxx). Other risks include hypertension, edema, and rare but severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. The European Medicines Agency and the FDA maintain strict warnings regarding its cardiovascular and gastrointestinal risks.

Pharmacology

Celecoxib functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme, which is induced during states of inflammation, while sparing the cyclooxygenase-1 (COX-1) enzyme important for gastric mucosa protection and platelet aggregation. Its mechanism involves reducing the synthesis of prostaglandins, specifically prostaglandin E2, at sites of inflammation. The drug is metabolized primarily in the liver by the cytochrome P450 enzyme CYP2C9, and its pharmacokinetics can be affected by genetic polymorphisms of this enzyme or by concomitant use of inhibitors like fluconazole.

History

Celecoxib was developed by the pharmaceutical company Searle (later part of Pharmacia and now Pfizer) and received FDA approval in December 1998. Its development was part of a concerted effort to create NSAIDs with improved gastrointestinal safety profiles, following research into the distinct roles of COX-1 and COX-2 by scientists like John Vane. The drug's market position was significantly affected by the Vioxx withdrawal and the subsequent findings of the Celecoxib Long-term Arthritis Safety Study (CLASS) and the Adenoma Prevention with Celecoxib (APC) trial, which informed ongoing regulatory reviews by the FDA.

Society and culture

Celecoxib is marketed under the brand name Celebrex by Pfizer and is available as a generic drug in many countries. Its high cost and cardiovascular risk profile have been subjects of debate within healthcare systems like the National Health Service (NHS) in the United Kingdom. The drug has been featured in high-profile litigation and discussions on pharmaceutical marketing practices, often referenced alongside the Vioxx controversy. It remains a commonly prescribed agent, with its use carefully weighed against alternatives like naproxen in guidelines from the American College of Cardiology.

Category:Drugs